Angiogenesis in cancer and other diseases
The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis is a hallmark of cancer and various ischaemic and inflammatory diseases. Concentrated efforts in this area of research are leading to the discovery of a growing number of pro- and anti-angiogenic molecules, some of which are already in clinical trials. The complex interactions among these molecules and how they affect vascular structure and function in different environments are now beginning to be elucidated. This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of vascularization is one of the landmarks of tumor environments [57,180].”
From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [180]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“This hypothesis formed the basis of the discovery of angiostatin, endostatin, vasculostatin and other endogenous inhibitors of angiogenesi”
BackgroundMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162 · cited 1×
“We now know there are various molecular players involved in these different mechanisms of vascular growt”
BackgroundSelf-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Self-citationO'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345 · cited 1×
“This hypothesis formed the basis of the discovery of angiostatin, endostatin, vasculostatin and other endogenous inhibitors of angiogenesi”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“However, caution is warranted as these hypoxia-inducible factors could also control cell deat”
BackgroundSelf-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationCancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054 · cited 1×
“In vivo selection of phage display libraries has recently yielded peptides (for example, amino-acid sequences RGD and NGR) that preferentially recognize vessels in subcutaneous tumours in mic”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Self-citationHelmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Self-citation
Research works printed but not linked: 8
- Greenblatt, M. & Shubik, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparant chamber technique. J. Natl Cancer Inst. 41, 111–124 (1968).
- Ehrmann, R. L. & Knoth, M. Choriocarcinoma: transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J. Natl Cancer Inst. 41, 1329 –1341 (1968).
- Folkman, J. in Cancer Medicine (eds Holland, J. F. et al.) 132– 152 (Decker, Ontario, Canada, 2000).
- Chang, Y. S. et al. Abundance of neoplastic cells in vessel walls of human tumor xenografts. Proc. Am. Assoc. Cancer Res. (in the press).
- Seljelid, R., Jozefowski, S. & Sveinbjornsson, B. Tumor stroma. Anticancer Res. 19, 4809–4822 (1999).
- Buschmann, I. & Schaper, W. The pathophysiology of the collateral circulation (arteriogenesis). J. Pathol. 190, 338–342 (2000). · doi:10.1002/(sici)1096-9896(200002)190:3<338::aid-path594>3.0.co;2-7
- Carmeliet, P. & Collen, D. Transgenic mouse models in angiogenesis and cardiovascular disease. J. Pathol. 190, 387–405 (2000). · doi:10.1002/(sici)1096-9896(200002)190:3<387::aid-path595>3.0.co;2-r
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1alpha/HRE/VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. (in the press).
Cited by
Items 301–400 of 1,084
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356
Mechanisms of Cancer Resistance to Immunotherapy
Bai, R., Chen, N., Li, L., Du, N., Bai, L., Lv, Z., Tian, H., & Cui, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01290 · Cited by 353
“Abnormal Neovascularization in TME Contributes to Resistance to Immunotherapy The massive production of proangiogenic factors such as VEGF in tumor tissues, as immunosuppressive factors, can inhibit DCs maturation by directly activating the NF-κB pathway, and on the other hand, they also can lead to abnormal and dysfu…”
BackgroundThe candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis
Garkavtsev, I., Kozin, S. V., Chernova, O., Xu, L., Winkler, F., Brown, E., Barnett, G. H., & Jain, R. K. (2004) · Nature · doi:10.1038/nature02329 · Cited by 353
“these genes was detected in U87MG cell lines with different ING4 status: control vector expression (V), ING4 overexpression (4) and ING4 downregulation (as-4).”
Self-citationAngiogenesis in Gliomas: Biology and Molecular Pathophysiology
Fischer, I., Gagner, J., Law, M., Newcomb, E. W., & Zagzag, D. (2005) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00115.x · Cited by 350
“In adult life it is observed in the female reproductive system and during wound healing (175) and in a wide range of pathologic settings, such as ischemic diseases, chronic inflammatory reactions, and neoplasia (35, 65).”
BackgroundChun, T.-H., Sabeh, F., Ota, I., Murphy, H., McDonagh, K. T., Holmbeck, K., Birkedal-Hansen, H., Allen, E. D., & Weiss, S. J. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200405001 · Cited by 349
“Although multiple proteolytic systems have been implicated in angiogenic events in vivo (Carmeliet and Jain, 2000; Pepper, 2001; Davis et al., 2002), attempts to identify enzymes critical to tissue remodeling per se have been complicated by the more recent appreciation that the substrate repertoire of MMPs extends to…”
BackgroundResultInfluentialSalvucci, O., Yao, L., Villalba, S., Sajewicz, A., Pittaluga, S., & Tosato, G. (2002) · Blood · doi:10.1182/blood.v99.8.2703 · Cited by 347
Transcriptional Control of Endothelial Cell Development
De Val, S., & Black, B. L. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.014 · Cited by 346
“In addition, vascularization of solid tumors is essential for their growth and eventual metastasis (Carmeliet and Jain, 2000; Stacker et al., 2002).”
BackgroundGold-Nanoparticle-Assisted Plasmonic Photothermal Therapy Advances Toward Clinical Application
Ali, M. R. K., Wu, Y., & El-Sayed, M. A. (2019) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.9b01961 · Cited by 346
PI3K/PTEN signaling in tumorigenesis and angiogenesis
Jiang, B.-H., & Liu, L.-Z. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.09.008 · Cited by 345
Combinatorial Regulation of Endothelial Gene Expression by Ets and Forkhead Transcription Factors
De Val, S., Chi, N. C., Meadows, S. M., Minovitsky, S., Anderson, J. P., Harris, I. S., Ehlers, M. L., Agarwal, P., Visel, A., Xu, S.-M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.10.049 · Cited by 343
“The Fox-Ets Interaction as a Target for Modulation of Vascular Growth and Remodeling Aberrant vessel growth is an important contributor to several prevalent disease states (Carmeliet and Jain, 2000).”
Khakoo, A. Y., & Finkel, T. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.090203.104149 · Cited by 343
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
“Additionally, plasmin- induced cleavage of both VEGF165 and VEGF189 releases a bioactive carboxy- terminal domain (111-165) of VEGF (19).”
BackgroundLee, V. K., Lanzi, A. M., Ngo, H., Yoo, S.-S., Vincent, P. A., & Dai, G. (2014) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-014-0340-0 · Cited by 342
Functional Hydrogels With Tunable Structures and Properties for Tissue Engineering Applications
Li, X., Sun, Q., Li, Q., Kawazoe, N., & Chen, G. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00499 · Cited by 340
Role of Fibrin Matrix in Angiogenesis
van HINSBERGH, V. W. M., COLLEN, A., & KOOLWIJK, P. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03526.x · Cited by 339
Xu, X. R., Zhang, D., Oswald, B. E., Carrim, N., Wang, X., Hou, Y., Zhang, Q., Lavalle, C., McKeown, T., Marshall, A. H., et al. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2016.1200008 · Cited by 338
Targeting the tumor vasculature to enhance T cell activity
Lanitis, E., Irving, M., & Coukos, G. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.011 · Cited by 338
Gunsilius, E., Duba, H.-C., Petzer, A. L., Kahler, C. M., Grunewald, K., Stockhammer, G., Gabl, C., Dirnhofer, S., Clausen, J., & Gastl, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02241-8 · Cited by 337
Zhang, C., Jugold, M., Woenne, E. C., Lammers, T., Morgenstern, B., Mueller, M. M., Zentgraf, H., Bock, M., Eisenhut, M., Semmler, W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1668 · Cited by 336
“Angiogenesis is an essential step for the growth and spread of malignant tumors (1, 2) and its extension correlates with the malignant potential of several cancers, including breast cancer, malignant melanoma, and skin squamous cell carcinoma (3–5).”
BackgroundTargeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel
Danhier, F., Vroman, B., Lecouturier, N., Crokart, N., Pourcelle, V., Freichels, H., Jérôme, C., Marchand-Brynaert, J., Feron, O., & Préat, V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.08.011 · Cited by 335
“Angiogenic endothelial cells may be considered as a major target for therapeutic intervention because they are easily accessible [7,8].”
BackgroundProtein kinases as targets for anticancer agents: from inhibitors to useful drugs
Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., et al. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00179-1 · Cited by 335
The Pivotal Role of Vascularization in Tissue Engineering
Auger, F. A., Gibot, L., & Lacroix, D. (2013) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071812-152428 · Cited by 334
Metabolic Reprogramming of Cancer-Associated Fibroblasts by IDH3α Downregulation
Zhang, D., Wang, Y., Shi, Z., Liu, J., Sun, P., Hou, X., Zhang, J., Zhao, S., Zhou, B. P., & Mi, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.006 · Cited by 333
“The development and progression of tumors are controlled not only by tumor cells but also by their surrounding stromal cells (Carmeliet and Jain, 2000; Rønnov-Jessen et al., 1996; Tlsty, 2001).”
BackgroundNanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
“These abnormal characteristics along with poorly formed fenestrations lead to leaky tumor vessels and irregular blood-flow within solid tumors [60, 61].”
BackgroundInositol-requiring enzyme 1α is a key regulator of angiogenesis and invasion in malignant glioma
Auf, G., Jabouille, A., Guérit, S., Pineau, R., Delugin, M., Bouchecareilh, M., Magnin, N., Favereaux, A., Maitre, M., Gaiser, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914072107 · Cited by 331
“A significant body of evidence also implicates CTGF, the multivalent ECM proteins SPARC, decorin, and THBS1, and the proteolytic enzymes and inhibitors PLAU,MMP-2, and TIMP-2 in invasion and angiogenesis (2, 14, 16, 18, 36).”
BackgroundDetection of circulating endothelial cells and endothelial progenitor cells by flow cytometry
Khan, S. S., Solomon, M. A., & McCoy, J. P. (2005) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.20040 · Cited by 331
“DOI: 10.1002/cyto.b.20040 Cytometry Part B (Clinical Cytometry) 64B:1–8 (2005)”
InfluentialGalectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response
Markowska, A. I., Liu, F.-T., & Panjwani, N. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090121 · Cited by 330
“, 2003), and nonocular diseases, such as cancer (Carmeliet and Jain, 2000) and rheumatoid arthritis (Koch, 1998).”
BackgroundDuluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24401 · Cited by 329
Cursiefen, C., Cao, J., Chen, L., Liu, Y., Maruyama, K., Jackson, D., Kruse, F. E., Wiegand, S. J., Dana, M. R., & Streilein, J. W. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1380 · Cited by 329
“tions of hypoxic and inflammatory hemangiogenesis, VEGF-A through VEGFR2-ligation has emerged as the main growth factor that induces hemangiogenesis.(12) Using the mouse model of normal-risk keratoplasty, the present study analyzed (1) whether lymphangiogenesis accompanies hemangiogenesis after normal-risk keratoplast…”
Backgroundvon Marschall, Z., Scholz, A., Cramer, T., Schafer, G., Schirner, M., Oberg, K., Wiedenmann, B., Hocker, M., & Rosewicz, S. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.437 · Cited by 328
Tumor-Host Interactions: A Far-Reaching Relationship
McAllister, S. S., & Weinberg, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4257 · Cited by 327
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis
Dirkx, A. E. M., oude Egbrink, M. G. A., Wagstaff, J., & Griffioen, A. W. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0905495 · Cited by 326
“Tumor angiogenesis is promoted by hypoxia, resulting in enhanced expression of angiogenic factors, such as vascular endothelial growth factor (VEGF), IL-8, and basic fibroblast growth factor (bFGF), and in decreased expression of angiogenesis inhibitors, such as platelet factor-4, thrombospondin, and angiostatin [5].”
BackgroundSánchez-Elsner, T., Botella, L. M., Velasco, B., Langa, C., & Bernabéu, C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207160200 · Cited by 326
Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes
Dadras, S. S., Lange-Asschenfeldt, B., Velasco, P., Nguyen, L., Vora, A., Muzikansky, A., Jahnke, K., Hauschild, A., Hirakawa, S., Mihm, M. C., et al. (2005) · Modern Pathology · doi:10.1038/modpathol.3800410 · Cited by 326
“21 as opposed to the traditional view of a passive role for the lymphatic endothelium during tumor lymphatic invasion and metastasis”
BackgroundCao, R., Eriksson, A., Kubo, H., Alitalo, K., Cao, Y., & Thyberg, J. (2004) · Circulation Research · doi:10.1161/01.res.0000118600.91698.bb · Cited by 324
“Penetration of soluble small and larger molecules across vascular endothelia is mediated by the following structures: (1) caveolae (plasmalemmal vesicles); (2) transendothelial channels (fused caveolae); (3) intercellular gaps; and (4) endothelial fenestrations.”
BackgroundMetabolic origins of spatial organization in the tumor microenvironment
Carmona-Fontaine, C., Deforet, M., Akkari, L., Thompson, C. B., Joyce, J. A., & Xavier, J. B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700600114 · Cited by 323
“Examples include the formation of multicellular structures such as blood vessels (11,12),coordinatedcollectiveinvasion(13),noncellautonomous paracrineeffects(14),and“divisionoflabor”betweendifferenttumorcells(15).”
BackgroundIntegrin αvβ3‐targeted cancer therapy
Liu, Z., Wang, F., & Chen, X. (2008) · Drug Development Research · doi:10.1002/ddr.20265 · Cited by 323
“…on the balance between pro-angiogenic molecules such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and epidermal growth factor (EGF), and anti-angiogenic molecules (e.g., angiostatin, endostatin, and thrombospondin) [Cai and Chen, 2006; Carmeliet and Jain, 2000].”
BackgroundOvercoming the Limits of Hypoxia in Photodynamic Therapy: A Carbonic Anhydrase IX-Targeted Approach
Jung, H. S., Han, J., Shi, H., Koo, S., Singh, H., Kim, H.-J., Sessler, J. L., Lee, J. Y., Kim, J.-H., & Kim, J. S. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b02396 · Cited by 323
CHAPLAIN, M. A. J., & LOLAS, G. (2005) · Mathematical Models and Methods in Applied Sciences · doi:10.1142/s0218202505000947 · Cited by 323
Hyaluronidase To Enhance Nanoparticle-Based Photodynamic Tumor Therapy
Gong, H., Chao, Y., Xiang, J., Han, X., Song, G., Feng, L., Liu, J., Yang, G., Chen, Q., & Liu, Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b00068 · Cited by 322
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
“Because vascular development in tumors occurs via angiogenesis, or the growth of new vessels from the surrounding vascular beds, and is triggered by angiogenic factors secreted by tumor cells (33), we predicted that BAY 43-9006 and siRNA-mediated inhibition of B-Raf were reducing the activity of a key angiogenic facto…”
BackgroundTian, X.-L., Kadaba, R., You, S.-A., Liu, M., Timur, A. A., Yang, L., Chen, Q., Szafranski, P., Rao, S., Wu, L., et al. (2004) · Nature · doi:10.1038/nature02320 · Cited by 321
Role of the tumor microenvironment in tumor progression and the clinical applications (Review)
YUAN, Y., JIANG, Y.-C., SUN, C.-K., & CHEN, Q.-M. (2016) · Oncology Reports · doi:10.3892/or.2016.4660 · Cited by 320
Arora, N., Martins, D., Ruggerio, D., Tousimis, E., Swistel, A. J., Osborne, M. P., & Simmons, R. M. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2008.06.015 · Cited by 320
“Its use in the field of medical oncology lies in the fact that tumors generally have an increase in blood supply and angiogenesis, as well as an increased metabolic rate, which in turn translates into increased temperature gradients compared to surrounding normal tissue.(1) Detecting these infrared “hotspots” and grad…”
BackgroundRoles of Matrix Metalloproteinases in Tumor Metastasis and Angiogenesis
Yoon, S.-O., Park, S.-J., Yun, C.-H., & Chung, A.-S. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.128 · Cited by 320
“Angiogenesis is necessary for persistent tumor growth, because the sprouting capillaries are conduits for gas exchange and nutrient supply (Carmeliet and Jain, 2000).”
Semenza, G. L. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21523 · Cited by 317
Stromal biology of pancreatic cancer
Chu, G. C., Kimmelman, A. C., Hezel, A. F., & DePinho, R. A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21209 · Cited by 317
“An emerging concept in the field is that pathologic tumor vasculature exhibits structural and molecular differences compared to mature vasculature whichmay in part be due to altered gene expression [Carmeliet and Jain, 2000].”
BackgroundBuilding drug delivery into tissue engineering design
Saltzman, W. M., & Olbricht, W. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd744 · Cited by 317
“In adults, the stepwise mechanisms of regeneration are being revealed in studies of angiogenesi”
BackgroundKrippl, P., Langsenlehner, U., Renner, W., Yazdani‐Biuki, B., Wolf, G., Wascher, T. C., Paulweber, B., Haas, J., & Samonigg, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11238 · Cited by 316
A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors
Heeschen, C., Weis, M., Aicher, A., Dimmeler, S., & Cooke, J. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14676 · Cited by 315
“These growth factors stimulate endothelial cells (ECs) in the existing vasculature to proliferate and to migrate through the tissue to form new endothelialized channels (1, 2).”
BackgroundCommon risk factors for heart failure and cancer
Meijers, W. C., & de Boer, R. A. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz035 · Cited by 314
“It is now generally accepted that there is an angiogenic switch that either tips towards a net absence of angiogenesis, or tips towards enhanced angiogenesis, where neovascularization is active and supports tumour growth.(111)”
BackgroundEndothelial Notch1 Activity Facilitates Metastasis
Wieland, E., Rodriguez-Vita, J., Liebler, S. S., Mogler, C., Moll, I., Herberich, S. E., Espinet, E., Herpel, E., Menuchin, A., Chang-Claude, J., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.007 · Cited by 314
Kudo, M., Han, K.-H., Ye, S.-L., Zhou, J., Huang, Y.-H., Lin, S.-M., Wang, C.-K., Ikeda, M., Chan, S. L., Choo, S. P., et al. (2020) · Liver Cancer · doi:10.1159/000507370 · Cited by 314
Inflammatory cell infiltration of tumors: Jekyll or Hyde
Talmadge, J. E., Donkor, M., & Scholar, E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9072-0 · Cited by 313
Sun, J., Shen, H., Shao, L., Teng, X., Chen, Y., Liu, X., Yang, Z., & Shen, Z. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01881-7 · Cited by 313
Nanomaterials for Cancer Therapy and Imaging
Bae, K. H., Chung, H. J., & Park, T. G. (2011) · Molecules and Cells · doi:10.1007/s10059-011-0051-5 · Cited by 313
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
“Pathophysiological conditions in the extracellular environment of the disease site offer excellent targets that can be exploited for designing drug delivery systems [93,94].”
BackgroundThe urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
“Given that in absence of microvascularization the tumors are unable to progress beyond a size of 2 mm, one of the new functional capabilities that must be acquired by cancer tissues in order to progress is to promote neoangiogenesis [1, 149].”
BackgroundClinical implications of cancer self-seeding
Comen, E., Norton, L., & Massagué, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.64 · Cited by 312
“However, CTCs re-entering the source-tumor itself should encounter a leaky neovasculature and a familiar microenvironment, factors that underlie the tenability of the concept of self-seeding”
BackgroundApigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways
Fang, J., Xia, C., Cao, Z., Zheng, J. Z., Reed, E., & Jiang, B.-H. (2005) · The FASEB Journal · doi:10.1096/fj.04-2175com · Cited by 312
A review of imaging techniques for systems biology
Kherlopian, A. R., Song, T., Duan, Q., Neimark, M. A., Po, M. J., Gohagan, J. K., & Laine, A. F. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-74 · Cited by 310
“The uptake of tracer into tissues is proportional to delivery, and so is a measure of perfusion [87].”
BackgroundAnti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
Schiffelers, R. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00240-2 · Cited by 310
Kudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2019) · Cancers · doi:10.3390/cancers11081084 · Cited by 309
“That is, giving TACE to intermediate-stage HCC patients with up-to-seven criteria out leads to a spike in the intra-tumoral concentration of VEGF, FGF or PDGF, suggesting that blockade of these receptors may prevent the effects of a surge in proangiogenic factors [39,40].”
BackgroundIn vitro anti-proliferative activities of ellagic acid
Losso, J. N., Bansode, R. R., Trappey, A., Bawadi, H. A., & Truax, R. (2004) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2004.06.004 · Cited by 309
“[3] Carmeliet P, Jain RK.”
BackgroundSgadari, C., Barillari, G., Toschi, E., Carlei, D., Bacigalupo, I., Baccarini, S., Palladino, C., Leone, P., Bugarini, R., Malavasi, L., et al. (2002) · Nature Medicine · doi:10.1038/nm0302-225 · Cited by 309
“Thus, bFGF and VEGF are crucial to the development and progression of all forms of KS as well as to the growth of solid tumor”
BackgroundHydrogels for Engineering of Perfusable Vascular Networks
Liu, J., Zheng, H., Poh, P., Machens, H.-G., & Schilling, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160715997 · Cited by 308
“In the human body, cells are usually found within a range of 100–200 μm from the next capillary that provides the cells with oxygen and nutrients [2].”
BackgroundMetalloproteinases and their inhibitors in tumor angiogenesis
Handsley, M. M., & Edwards, D. R. (2005) · International Journal of Cancer · doi:10.1002/ijc.20945 · Cited by 307
“To allow its growth beyond a certain critical size, a solid avascular tumor must develop its own blood supply in order to meet its growing metabolic requirements.(1)”
BackgroundEmerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis
Cao, Y. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1693 · Cited by 307
“The formation of new blood vessels involves the sprouting of new capillaries from pre-existing vessels (angiogenesis), the recruitment of stem cells that differentiate into endothelial precursor cells (vasculogenesis), and the division of large 'mother' vessels into smaller 'daughter' vessels (intussusception”
BackgroundYoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D. J., Wu, Y., Yanase, K., Namisaki, T., Yamazaki, M., et al. (2003) · Gut · doi:10.1136/gut.52.9.1347 · Cited by 307
Personal Authentication Using Hand Vein Triangulation and Knuckle Shape
Kumar, A., & Prathyusha, K. V. (2009) · IEEE Transactions on Image Processing · doi:10.1109/tip.2009.2023153 · Cited by 307
“Diabetes, hypertension, atherosclerosis, metabolic disorders [25], and tumors [26] are some diseases which affect the vascular systems and made it thick or thin.”
BackgroundBiodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Tabrizi, M., Bornstein, G. G., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-009-9157-5 · Cited by 305
“disorganized and irregularly shaped, and the tumor vessel wall may be lined with only cancer cells or a “mosaic” layer of cancer and endothelial cells (61).”
BackgroundScully, C. M., & Sebastián, J. V. B. (2009) · Oral Diseases · doi:10.1111/j.1601-0825.2009.01563.x · Cited by 305
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Holden, S. N., Eckhardt, S. G., Basser, R., de Boer, R., Rischin, D., Green, M., Rosenthal, M. A., Wheeler, C., Barge, A., & Hurwitz, H. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi247 · Cited by 304
“Recognition of the role of angiogenesis as a fundamental requirement for tumor growth has led to the identification and assessment of a number of agents with antiangiogenic activity [1].”
BackgroundCurrent approaches to the treatment of metastatic brain tumours
Owonikoko, T. K., Arbiser, J., Zelnak, A., Shu, H.-K. G., Shim, H., Robin, A. M., Kalkanis, S. N., Whitsett, T. G., Salhia, B., Tran, N. L., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.25 · Cited by 304
Pawlik, T. M., Reyes, D. K., Cosgrove, D., Kamel, I. R., Bhagat, N., & Geschwind, J.-F. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1021 · Cited by 304
Controlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
“These properties arise from intratumoural signals (such as pro-angiogenic and immunosuppressive signals) 219 and the phenotype of different stroma cells such as TECs, cancer-associated fibroblasts (CAFs) and tumour-associated macrophages 220–222 .”
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302
Oxidized LDL, LOX-1 and Atherosclerosis
Mitra, S., Goyal, T., & Mehta, J. L. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6341-5 · Cited by 300
“Angiogenesis is observed in atherosclerotic and cancerous tissues and plays an important role in progression of these diseases [87, 88].”
BackgroundElson, D. A., Thurston, G., Huang, L. E., Ginzinger, D. G., McDonald, D. M., Johnson, R. S., & Arbeit, J. M. (2001) · Genes & Development · doi:10.1101/gad.914801 · Cited by 299
Jackson, A., O'Connor, J. P. B., Parker, G. J. M., & Jayson, G. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0238 · Cited by 299
Jain, R. K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00306-6 · Cited by 298
Self-citationDendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer
Curiel, T. J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M., Wei, S., Zou, L., Kryczek, I., Hoyle, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1272 · Cited by 297
“known to modulate blood vessel formation in some settings (11),”
BackgroundSelf-citationThe role of pore size on vascularization and tissue remodeling in PEG hydrogels
Chiu, Y.-C., Cheng, M.-H., Engel, H., Kao, S.-W., Larson, J. C., Gupta, S., & Brey, E. M. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.066 · Cited by 297
ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway
Zhang, Q., Lu, S., Li, T., Yu, L., Zhang, Y., Zeng, H., Qian, X., Bi, J., & Lin, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1156-5 · Cited by 297
A Cell-Based Model Exhibiting Branching and Anastomosis during Tumor-Induced Angiogenesis
Bauer, A. L., Jackson, T. L., & Jiang, Y. (2007) · Biophysical Journal · doi:10.1529/biophysj.106.101501 · Cited by 297
“DEChemotaxis 1⁄4ms1⁄2Vðx ~Þ Vðx ~9Þ : (3)”
BackgroundSasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes & Development · doi:10.1101/gad.198200.112 · Cited by 296
Exercise-dependent regulation of the tumour microenvironment
Koelwyn, G. J., Quail, D. F., Zhang, X., White, R. M., & Jones, L. W. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.78 · Cited by 296
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
“Without blood vessels tumours cannot grow beyond a critical size or metastasise to another organ and therefore inhibition of such processes could be a strategy for tumour arrest (Carmeliet and Jain, 2000).”
BackgroundFoekens, J. A., Peters, H. A., Grebenchtchikov, N. I., Look, M. P., Gelder, M. E. M., Geurts-Moespot, A. J., van der Kwast, T., Sweep, F. C. G. J., & Klijn, J. G. M. (2001) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 332
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
Dong, J., Grunstein, J., Tejada, M., Peale, F., Frantz, G., Liang, W., Bai, W., Yu, L., Kowalski, J., Liang, X., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600289 · Cited by 295
“Angiogenesis, the formation of new blood vessels, is crucial for tumor growth, as tumor cells require oxygen and nutrients for proliferation and survival (Folkman, 1995; Carmeliet and Jain, 2000).”
BackgroundConditional mouse models of sporadic cancer
Jonkers, J., & Berns, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc777 · Cited by 294
(1926) · The American Journal of Surgery · doi:10.1016/s0002-9610(26)90068-8 · Cited by 293
Inhibition of tumor angiogenesis by cannabinoids
Blázquez, C., Casanova, M. L., Planas, A., Gómez del Pulgar, T., Villanueva, C., Fernández‐Aceñero, M. J., Aragonés, J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0795fje · Cited by 292
“Cannabinoid administration was associated with a notable decrease in the expression of the major proangiogenic factors VEGF and Ang2, which are essential for the vascularization of gliomas and many other types of tumors such as those from mammary gland, lung, and skin (13, 22, 26, 27).”
BackgroundInfluentialOxygen and Pt(II) self-generating conjugate for synergistic photo-chemo therapy of hypoxic tumor
Xu, S., Zhu, X., Zhang, C., Huang, W., Zhou, Y., & Yan, D. (2018) · Nature Communications · doi:10.1038/s41467-018-04318-1 · Cited by 292
Kozin, S. V., Boucher, Y., Hicklin, D. J., Böhlen, P., Jain, R. K., & Suit, H. D. (2001) · PubMed · Cited by 291
Self-citation3D Bioprinted Human Skeletal Muscle Constructs for Muscle Function Restoration
Kim, J. H., Seol, Y.-J., Ko, I. K., Kang, H.-W., Lee, Y. K., Yoo, J. J., Atala, A., & Lee, S. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-29968-5 · Cited by 290
Nissen, L. J., Cao, R., Hedlund, E.-M., Wang, Z., Zhao, X., Wetterskog, D., Funa, K., Bråkenhielm, E., & Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32479 · Cited by 290
“For example, VEGF is usually expressed at high levels in most tumors and has become an obviously therapeutic target for cancer therapy (1, 3, 6, 14).”
BackgroundOxygen Sensors at the Crossroad of Metabolism
Aragonés, J., Fraisl, P., Baes, M., & Carmeliet, P. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.001 · Cited by 290
Self-citationLi, H., & Chang, J. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.02.014 · Cited by 290
“However, for the survival of a tissue-engineered construct with size larger than the diffusion limit of oxygen after its implantation in vivo, the tissue has to be vascularized, which means that a capillary network capable of delivering nutrients to the cells has to be formed within the construct [1].”
Background
Metadata
- Authors
- Carmeliet, P., & Jain, R. K.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Harvard University (US)
- ORCID
- Carmeliet, Peter
- Venue
- Nature
- Published
- 2000-09
- Volume
- 407
- Issue
- 6801
- Pages
- 249-257
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1573363574
- Cited by
- 9,070
- References
- 72
- Citations by year
- 2026: 166 · 2025: 208 · 2024: 246 · 2023: 330 · 2022: 335 · 2021: 381 · 2020: 368 · 2019: 349 · 2018: 375 · 2017: 380 · 2016: 378 · 2015: 364 · 2014: 414 · 2013: 412 · 2012: 416
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- pathological angiogenesis, cancer, ischemic diseases, inflammatory diseases, anti-angiogenic therapy, clinical trials
- MeSH terms
- Animals, Disease, Humans, Lymphokines, Neoplasms, Neovascularization, Pathologic, Endothelial Growth Factors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.